MATTHEW LEHNER-GULOTTA: Open Payments
NPI 1801675517 · CHARLOTTESVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$287 in 13 payments from 10 companies in 2025. Trend: 2023 $16 · 2024 $188 · 2025 $287
Food & beverage: $287
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $62 |
| PFIZER INC. | 2 | $44 |
| Biogen, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| Amgen Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Exact Sciences Corporation | 1 | $17 |
Products named: QULIPTA, PREVNAR 20, SKYCLARYS, CAPLYTA, OTEZLA, REXULTI, GARDASIL 9, Dexcom G6 Transmitter.
Industry payments across VA — which companies pay providers there.
